The C242T polymorphism of the p22-phox gene (CYBA) is associated with higher left ventricular mass in Brazilian hypertensive patients

Carregando...
Imagem de Miniatura
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
SCHREIBER, Roberto
FERREIRA-SAE, Maria C.
RONCHI, Juliana A.
PIO-MAGALHAES, Jose A.
CIPOLLI, Jose A.
MATOS-SOUZA, Jose R.
MILL, Jose G.
VERCESI, Anibal E.
FRANCHINI, Kleber G.
Citação
BMC MEDICAL GENETICS, v.12, article ID 114, 6p, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Reactive oxygen species have been implicated in the physiopathogenesis of hypertensive end-organ damage. This study investigated the impact of the C242T polymorphism of the p22-phox gene (CYBA) on left ventricular structure in Brazilian hypertensive subjects. Methods: We cross-sectionally evaluated 561 patients from 2 independent centers [Campinas (n = 441) and Vitoria (n = 120)] by clinical history, physical examination, anthropometry, analysis of metabolic and echocardiography parameters as well as p22-phox C242T polymorphism genotyping. In addition, NADPH-oxidase activity was quantified in peripheral mononuclear cells from a subgroup of Campinas sample. Results: Genotype frequencies in both samples were consistent with the Hardy-Weinberg equilibrium. Subjects with the T allele presented higher left ventricular mass/height(2.7) than those carrying the CC genotype in Campinas (76.8 +/- 1.6 vs 70.9 +/- 1.4 g/m(2.7); p = 0.009), and in Vitoria (45.6 +/- 1.9 vs 39.9 +/- 1.4 g/m(2.7); p = 0.023) samples. These results were confirmed by stepwise regression analyses adjusted for age, gender, blood pressure, metabolic variables and use of anti-hypertensive medications. In addition, increased NADPH-oxidase activity was detected in peripheral mononuclear cells from T allele carriers compared with CC genotype carriers (p = 0.03). Conclusions: The T allele of the p22-phox C242T polymorphism is associated with higher left ventricular mass/height(2.7) and increased NADPH-oxidase activity in Brazilian hypertensive patients. These data suggest that genetic variation within NADPH-oxidase components may modulate left ventricular remodeling in subjects with systemic hypertension.
Palavras-chave
p22-phox, left ventricle, hypertension, polymorphism, NADPH-oxidase
Referências
  1. Ruilope LM, 2008, AM J HYPERTENS, V21, P500, DOI 10.1038/ajh.2008.16
  2. Cipolli JAA, 2009, HYPERTENS RES, V32, P956, DOI 10.1038/hr.2009.134
  3. Lang RM, 2006, EUR J ECHOCARDIOGR, V7, P79, DOI 10.1016/j.euje.2005.12.014
  4. Sales ML, 2010, CLIN CHIM ACTA, V411, P744, DOI 10.1016/j.cca.2010.02.006
  5. Sales ML, 2010, AM J HYPERTENS, V23, P649, DOI 10.1038/ajh.2010.24
  6. [Anonymous], 2001, JAMA, V285, P2486
  7. Inoue N, 1998, CIRCULATION, V97, P135
  8. Murdoch CE, 2006, CARDIOVASC RES, V71, P208, DOI 10.1016/j.cardiores.2006.03.016
  9. DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898
  10. Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200
  11. Maytin M, 2004, CIRCULATION, V109, P1168, DOI 10.1161/01.CIR.0000117229.60628.2F
  12. Zalba G, 2005, ANTIOXID REDOX SIGN, V7, P1327, DOI 10.1089/ars.2005.7.1327
  13. Sales ML, 2007, J HUM HYPERTENS, V21, P504, DOI 10.1038/sj.jhh.1002170
  14. Cahilly C, 2000, CIRC RES, V86, P391
  15. Degasperi GR, 2009, METABOLISM, V58, P1087, DOI 10.1016/j.metabol.2009.04.002
  16. Di Castelnuovo A, 2008, THROMB HAEMOSTASIS, V99, P594, DOI 10.1160/TH07-08-0480
  17. Fan M, 2006, AM HEART J, V152, P538, DOI 10.1016/j.ahj.2006.02.018
  18. Hayaishi-Okano R, 2003, DIABETES CARE, V26, P458, DOI 10.2337/diacare.26.2.458
  19. Ito D, 2000, STROKE, V31, P936
  20. Kim KI, 2007, INT J CARDIOL, V123, P18, DOI 10.1016/j.ijcard.2006.11.105
  21. Li A, 1999, AM J MED GENET, V86, P57, DOI 10.1002/(SICI)1096-8628(19990903)86:1<57::AID-AJMG11>3.0.CO;2-R
  22. Moreno MU, 2006, J HYPERTENS, V24, P1299, DOI 10.1097/01.hjh.0000234110.54110.56
  23. Nadruz W, 2004, HYPERTENSION, V43, P1060, DOI 10.1161/01.HYP.0000124252.43470.2c
  24. Pereira AC, 2004, KIDNEY INT, V65, P1026, DOI 10.1111/j.1523-1755.2004.00479.x
  25. Pio-Magalhaes JA, 2008, HYPERTENS RES, V31, P1177, DOI 10.1291/hypres.31.1177
  26. San José Gorka, 2008, Clin Sci (Lond), V114, P173, DOI 10.1042/CS20070130
  27. Shimo-Nakanishi Y, 2004, ATHEROSCLEROSIS, V175, P109, DOI 10.1016/j.atherosclerosis.2004.01.043
  28. Wang Y, 2006, BIOCHEM PHARMACOL, V72, P881, DOI 10.1016/j.bcp.2006.06.032
  29. Wyche KE, 2004, HYPERTENSION, V43, P1246, DOI 10.1161/01.HYP.0000126579.50711.62
  30. Yang M, 2005, AM J HYPERTENS, V18, P1329, DOI 10.1016/j.amjhyper.2005.04.012